A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge

Yfat Yahalom-Ronen, Hadas Tamir, Sharon Melamed, Boaz Politi, Ohad Shifman, Hagit Achdout, Einat B. Vitner, Ofir Israeli, Elad Milrot, Dana Stein, Inbar Cohen-Gihon, Shlomi Lazar, Hila Gutman, Itai Glinert, Lilach Cherry, Yaron Vagima, Shirley Lazar, Shay Weiss, Amir Ben-Shmuel, Roy Avraham, Reut Puni, Edith Lupu, Elad Bar-David, Assa Sittner, Noam Erez, Ran Zichel, Emanuelle Mamroud, Ohad Mazor, Haim Levy, Orly Laskar, Shmuel Yitzhaki, Shmuel C. Shapira, Anat Zvi, Adi Beth-Din, Nir Paran () and Tomer Israely ()
Additional contact information
Yfat Yahalom-Ronen: Israel Institute for Biological Research
Hadas Tamir: Israel Institute for Biological Research
Sharon Melamed: Israel Institute for Biological Research
Boaz Politi: Israel Institute for Biological Research
Ohad Shifman: Israel Institute for Biological Research
Hagit Achdout: Israel Institute for Biological Research
Einat B. Vitner: Israel Institute for Biological Research
Ofir Israeli: Israel Institute for Biological Research
Elad Milrot: Israel Institute for Biological Research
Dana Stein: Israel Institute for Biological Research
Inbar Cohen-Gihon: Israel Institute for Biological Research
Shlomi Lazar: Israel Institute for Biological Research
Hila Gutman: Israel Institute for Biological Research
Itai Glinert: Israel Institute for Biological Research
Lilach Cherry: Israel Institute for Biological Research
Yaron Vagima: Israel Institute for Biological Research
Shirley Lazar: Israel Institute for Biological Research
Shay Weiss: Israel Institute for Biological Research
Amir Ben-Shmuel: Israel Institute for Biological Research
Roy Avraham: Israel Institute for Biological Research
Reut Puni: Israel Institute for Biological Research
Edith Lupu: Israel Institute for Biological Research
Elad Bar-David: Israel Institute for Biological Research
Assa Sittner: Israel Institute for Biological Research
Noam Erez: Israel Institute for Biological Research
Ran Zichel: Israel Institute for Biological Research
Emanuelle Mamroud: Israel Institute for Biological Research
Ohad Mazor: Israel Institute for Biological Research
Haim Levy: Israel Institute for Biological Research
Orly Laskar: Israel Institute for Biological Research
Shmuel Yitzhaki: Israel Institute for Biological Research
Shmuel C. Shapira: Israel Institute for Biological Research
Anat Zvi: Israel Institute for Biological Research
Adi Beth-Din: Israel Institute for Biological Research
Nir Paran: Israel Institute for Biological Research
Tomer Israely: Israel Institute for Biological Research

Nature Communications, 2020, vol. 11, issue 1, 1-13

Abstract: Abstract The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of an efficient and cost-effective vaccine, suitable for mass immunization. Here, we show the development of a replication competent recombinant VSV-∆G-spike vaccine, in which the glycoprotein of VSV is replaced by the spike protein of SARS-CoV-2. In-vitro characterization of this vaccine indicates the expression and presentation of the spike protein on the viral membrane with antigenic similarity to SARS-CoV-2. A golden Syrian hamster in-vivo model for COVID-19 is implemented. We show that a single-dose vaccination results in a rapid and potent induction of SARS-CoV-2 neutralizing antibodies. Importantly, vaccination protects hamsters against SARS-CoV-2 challenge, as demonstrated by the abrogation of body weight loss, and alleviation of the extensive tissue damage and viral loads in lungs and nasal turbinates. Taken together, we suggest the recombinant VSV-∆G-spike as a safe, efficacious and protective vaccine against SARS-CoV-2.

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-20228-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-20228-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-20228-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().